Dóchas Life Sciences’ Post

New, Emerging Treatment Options for Patients With Multiple Myeloma: In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma. #finance #pharmacy #lifesciences

Relapsed/Refractory Multiple Myeloma Treatment Advances With Three BiTE Therapy Options: FDA-approved BiTE therapies for relapsed/refractory multiple myeloma show promising response rates, offering off-the-shelf alternatives to CAR T therapy. #finance #pharmacy #lifesciences

Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Is Standard of Care for High-Risk Early-Stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study provide evidence of improved long-term outcomes from this pembrolizumab-based regimen. #finance #pharmacy #lifesciences

Another day, another life-changing scientific break through. Parkinson's particularly hits a raw nerve. Anyone who's seen a senior citizen suffering from this terrible affliction has got to feel some joy today. The bizarre paradox of America: The world's best medical innovation ecosystem coupled with the world's worst care delivery system. And "system" is being generous. The better word is probably "situation." #Biotech #Biotechnology #Bigpharma #Pharmaceutical #Parkinsons #Neurology

In one of the most highly anticipated clinical trial readouts this year, an #RNA silencing treatment developed by Alnylam Pharmaceuticals reduced the risk of death, heart-related hospital visits and hospitalizations by 28% compared to placebo in patients with a heart muscle disease. The results, announced Monday, pave the way for Alnylam’s therapy vutrisiran to become the first RNA silencing therapy on the market for ATTR amyloidosis with cardiomyopathy, a condition in which misfolded proteins build up in the heart and can result in heart failure. If approved, Alnylam could enter a multibillion-dollar market currently dominated by Pfizer. #clinicaltrials #clinicalresults #readout #RNAsilencing #heartmuscledisease #vutrisiran #heartdisease #cardiology #cardio #ATTRcardiomyopathy #patients #PhaseIII #clinicaldata

AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as Monotherapy for Parkinson’s Disease AbbVie has announced positive topline results from its Phase 3 TEMPO-1 trial, which evaluated tavapadon as a monotherapy for early-stage Parkinson’s disease. Tavapadon met the primary endpoint, significantly improving motor symptoms, as measured by the MDS-UPDRS Parts II and III combined scores at Week 26. It also achieved a key secondary endpoint, showing improvements in daily motor functions. Dr. Primal Kaur, MD, MBA, Senior Vice President at AbbVie, emphasized the importance of these findings for addressing unmet patient needs in Parkinson’s. Additional results from the Phase 3 TEMPO-2 trial are expected by the end of 2024. For more details please click the link! https://lnkd.in/dqfjbeNa #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

CAR T Cell, Bispecific Therapies: Enhancing Treatment for Patients With Hematological Malignancies: Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, discusses the impact of CAR T cell and bispecific therapies in treatment of patients with hematological malignancies. #finance #pharmacy #lifesciences

Pediatric Low-Grade Glioma: FDA Grants Accelerated Approval for Ojemda in Treating Children The FDA has granted accelerated approval to Day One Biopharmaceuticals' Ojemda (tovorafenib) for the treatment of pediatric low-grade glioma (pLGG) in patients aged 6 months and older with relapsed or refractory disease and specific genetic alterations. This marks a significant advancement in the treatment of pediatric low-grade glioma, as Ojemda is the first systemic therapy approved for this patient population with BRAF alterations. The approval represents a breakthrough in pediatric oncology and provides a much-needed treatment option. Ojemda's approval is a result of collaboration between researchers, clinicians, regulatory agencies, patient advocacy groups, and industry partners. The availability of Ojemda offers hope for patients and families and ushers in a new era of precision medicine in pediatric oncology. The approval is based on data from the Phase II FIREFLY-1 trial, which showed promising efficacy outcomes. Ojemda has a manageable safety profile and common adverse effects include rash, fatigue, and gastrointestinal symptoms. The approval of Ojemda is a significant milestone in the management of pLGG and addresses critical unmet needs in pediatric oncology. For more details please click the link! https://lnkd.in/gDX-eAAG #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Rituximab, Magrolimab With Chemotherapy Modestly Effective and Well-Tolerated in Patients With R/R DLBCL: These results indicate the combination’s long-term effectiveness in a population with limited treatment options. #finance #pharmacy #lifesciences

Breakthrough in Duchenne Muscular Dystrophy Treatment: FDA Greenlights Duvyzat, First of Its Kind The FDA has approved Duvyzat, the first nonsteroidal medication for all genetic variants of Duchenne Muscular Dystrophy (DMD). Duvyzat, an HDAC inhibitor, reduces inflammation and muscle loss. The approval is based on the successful EPIDYS trial, which showed improved physical function in Duvyzat-treated patients compared to placebo. Common side effects include diarrhea and abdominal pain. This approval marks a milestone for DMD treatment and patient care. For more details please click the link! https://lnkd.in/dEmuZ-VT #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical